236 related articles for article (PubMed ID: 11422016)
1. Population pharmacokinetics of carbamazepine in Singapore epileptic patients.
Chan E; Lee HS; Hue SS
Br J Clin Pharmacol; 2001 Jun; 51(6):567-76. PubMed ID: 11422016
[TBL] [Abstract][Full Text] [Related]
2. Determination of phenobarbitone population clearance values for physically and mentally handicapped Chinese children with epilepsy.
Chan E; Chan K; Teoh R
J Clin Pharm Ther; 1997; 22(5-6):399-403. PubMed ID: 19160725
[TBL] [Abstract][Full Text] [Related]
3. Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling.
Yukawa E; To H; Ohdo S; Higuchi S; Aoyama T
Eur J Clin Pharmacol; 1998 Mar; 54(1):69-74. PubMed ID: 9591934
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients.
Jankovic SM; Jovanovic D; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2008 Nov; 30(9):707-13. PubMed ID: 19229380
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
[TBL] [Abstract][Full Text] [Related]
6. Phenobarbital pharmacokinetics in old age: a case-matched evaluation based on therapeutic drug monitoring data.
Messina S; Battino D; Croci D; Mamoli D; Ratti S; Perucca E
Epilepsia; 2005 Mar; 46(3):372-7. PubMed ID: 15730534
[TBL] [Abstract][Full Text] [Related]
7. Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients.
Vučićević K; Jovanović M; Golubović B; Kovačević SV; Miljković B; Martinović Ž; Prostran M
Eur J Clin Pharmacol; 2015 Feb; 71(2):183-90. PubMed ID: 25380628
[TBL] [Abstract][Full Text] [Related]
8. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of carbamazepine in adults with epilepsy.
Graves NM; Brundage RC; Wen Y; Cascino G; So E; Ahman P; Rarick J; Krause S; Leppik IE
Pharmacotherapy; 1998; 18(2):273-81. PubMed ID: 9545146
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data.
Jiao Z; Shi XJ; Zhao ZG; Zhong MK
J Clin Pharm Ther; 2004 Jun; 29(3):247-56. PubMed ID: 15153086
[TBL] [Abstract][Full Text] [Related]
11. A model for estimating individualized valproate clearance values in children.
Botha JH; Gray AL; Miller R
J Clin Pharmacol; 1995 Oct; 35(10):1020-4. PubMed ID: 8568010
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic modeling of valproate from clinical data in Serbian epileptic patients.
Jankovic SM; Milovanovic JR
Methods Find Exp Clin Pharmacol; 2007 Dec; 29(10):673-9. PubMed ID: 18200330
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis.
Milovanovic JR; Jankovic SM
Int J Clin Pharmacol Ther; 2011 Jul; 49(7):428-36. PubMed ID: 21726493
[TBL] [Abstract][Full Text] [Related]
14. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data.
Yukawa E; Aoyama T
J Clin Pharmacol; 1996 Aug; 36(8):752-9. PubMed ID: 8877681
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing topiramate clearance in adult patients with epilepsy: A population pharmacokinetic analysis.
Bae EK; Lee J; Shin JW; Moon J; Lee KJ; Shin YW; Kim TJ; Shin D; Jang IJ; Lee SK
Seizure; 2016 Apr; 37():8-12. PubMed ID: 26908152
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing valproate pharmacokinetics in children and adults.
Jankovic SM; Milovanovic JR; Jankovic S
Int J Clin Pharmacol Ther; 2010 Nov; 48(11):767-75. PubMed ID: 20979937
[TBL] [Abstract][Full Text] [Related]
17. Determination of phenobarbitone population clearance values for South African children.
Botha JH; Gray AL; Miller R
Eur J Clin Pharmacol; 1995; 48(5):381-3. PubMed ID: 8641326
[TBL] [Abstract][Full Text] [Related]
18. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening.
Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
J Pharm Pharmacol; 1997 Aug; 49(8):751-6. PubMed ID: 9379350
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of valproate in Mexican children with epilepsy.
Correa T; Rodríguez I; Romano S
Biopharm Drug Dispos; 2008 Dec; 29(9):511-20. PubMed ID: 19067436
[TBL] [Abstract][Full Text] [Related]
20. Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics.
Yukawa E; To H; Ohdo S; Higuchi S; Aoyama T
J Clin Pharmacol; 1997 Dec; 37(12):1160-7. PubMed ID: 9506012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
